microfluidics

Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.

The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years. 

The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.